Cangrelor (tetrasodium)

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP) -induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist[1][2].

Product Specifications

CAS Number

[163706-36-3]

Product Name Alternative

AR-C69931MX (tetrasodium)

UNSPSC

12352005

Hazard Statement

H302

Target

P2Y Receptor

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Purity

99.96

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@@H](O)[C@H](N2C3=NC(SCCC(F)(F)F)=NC(NCCSC)=C3N=C2)O[C@@H]1COP(OP(C(Cl)(P(O[Na])(O[Na])=O)Cl)(O[Na])=O)(O[Na])=O

Molecular Formula

C17H21Cl2F3N5Na4O12P3S2

Molecular Weight

864.29

Precautions

H302

References & Citations

[1]Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7 (17) :408.|[2]Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.|[3]Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15 (6) :1223-1235.